LU92033I2 - Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®) - Google Patents

Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®)

Info

Publication number: LU92033I2
Authority: LU; Luxembourg
Prior art keywords: sub; atoms; nitrogen; formula; fused
Prior art date: 2001-07-31

Application number

LU92033C

Other languages

English (en)

Other versions

LU92033I9 (fr

Original Assignee

Genzyme Global S A R L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-31

Filing date

2012-06-27

Publication date

2012-08-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92033(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-27 Application filed by Genzyme Global S A R L filed Critical Genzyme Global S A R L

2012-08-27 Publication of LU92033I2 publication Critical patent/LU92033I2/fr

2019-01-03 Publication of LU92033I9 publication Critical patent/LU92033I9/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Diabetes (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LU92033C 2001-07-31 2012-06-27 Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®) LU92033I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US30919601P	2001-07-31	2001-07-31
US38215502P	2002-05-20	2002-05-20
PCT/US2002/024212 WO2003011277A2 (fr)	2001-07-31	2002-07-30	Methodes de mobilisation de cellules souches/embryonnaires

Publications (2)

Publication Number	Publication Date
LU92033I2 true LU92033I2 (fr)	2012-08-27
LU92033I9 LU92033I9 (fr)	2019-01-03

Family

ID=26976666

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU92033C LU92033I2 (fr)	2001-07-31	2012-06-27	Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®)
LU00139C LUC00139I2 (fr)	2001-07-31	2019-11-26

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LU00139C LUC00139I2 (fr)	2001-07-31	2019-11-26

Country Status (28)

Country	Link
US (9)	US6987102B2 (fr)
EP (3)	EP2371361B1 (fr)
JP (2)	JP5137288B2 (fr)
KR (2)	KR100996378B1 (fr)
CN (2)	CN102302493B (fr)
AT (1)	ATE538785T1 (fr)
AU (1)	AU2002318927B2 (fr)
BE (1)	BE2019C544I2 (fr)
BR (1)	BRPI0211570B8 (fr)
CA (1)	CA2455559C (fr)
CY (4)	CY1112633T1 (fr)
DK (2)	DK2371361T3 (fr)
ES (2)	ES2742730T3 (fr)
FR (2)	FR12C0042I1 (fr)
HU (1)	HUP0402360A2 (fr)
IL (2)	IL159312A0 (fr)
LT (2)	LT2371361T (fr)
LU (2)	LU92033I2 (fr)
MX (1)	MXPA04000982A (fr)
NL (2)	NL300537I2 (fr)
NO (4)	NO336989B1 (fr)
NZ (1)	NZ530169A (fr)
PL (1)	PL364673A1 (fr)
PT (2)	PT2371361T (fr)
RU (1)	RU2309741C2 (fr)
SI (2)	SI2371361T1 (fr)
WO (1)	WO2003011277A2 (fr)
ZA (1)	ZA200400658B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
JP5137288B2 (ja) *	2001-07-31	2013-02-06	アノーメッドインコーポレイティド	前駆／幹細胞を動員する方法
US7354932B2 (en) *	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN1596255A (zh)	2001-12-21	2005-03-16	阿诺麦德股份有限公司	具有强效的与趋化因子受体结合的杂环化合物
JP4667241B2 (ja) *	2003-06-27	2011-04-06	旭化成株式会社	細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株
WO2005002522A2 (fr) *	2003-06-30	2005-01-13	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	Compositions et methodes pour traiter une ischemie tissulaire
US7417026B2 (en)	2003-08-13	2008-08-26	Children's Hospital Medical Center	Mobilization of hematopoietic cells
JP2007535479A (ja)	2003-08-13	2007-12-06	チルドレンズホスピタルメディカルセンター	ＧＴＰａｓｅを調節するためのキメラペプチド
IL158868A0 (en) *	2003-11-13	2004-05-12	Yeda Res & Dev	Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (fr) *	2004-04-20	2005-11-03	Bayer Healthcare Ag	Moyens diagnostiques et therapeutiques pour maladies associees au recepteur 4 de la chimiokine cxc (cxcr4)
EP1796716A4 (fr) *	2004-08-13	2010-09-08	Anormed Inc	Combinaisons de chimiokines pour mobiliser des cellules progenitrices/souches
US7785582B2 (en) *	2004-09-07	2010-08-31	Johnson Lanny L	Use of synovium and omentum for tissue engineering
US8182806B2 (en) *	2004-09-07	2012-05-22	Johnson Lanny L	Synovial villi for use with tissue engineering
US9789171B2 (en) *	2004-11-05	2017-10-17	The General Hospital Corporation	Anti-fugetactic agents for the treatment of ovarian cancer
AU2006259630B2 (en)	2005-06-13	2011-10-27	Cleveland Biolabs, Inc.	Methods of protecting against apoptosis using lipopeptides
CA2619828A1 (fr) *	2005-08-19	2007-02-22	Genzyme Corporation	Methodes permettant d'augmenter l'efficacite d'une chimiotherapie
WO2007025166A2 (fr) *	2005-08-25	2007-03-01	Repair Technologies, Inc.	Dispositifs, compositions et methodes de protection et de reparation de cellules et de tissus
US7927630B2 (en) *	2005-09-12	2011-04-19	Johnson Lanny L	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US8518349B2 (en)	2005-09-12	2013-08-27	Lanny Johnson	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) *	2005-11-18	2007-05-24	Rensselaer Polytechnic Institute	Stem cells within gel microenvironments
AU2006340074A1 (en) *	2006-02-24	2007-09-20	Genzyme Corporation	Methods for increasing blood flow and/or promoting tissue regeneration
WO2007108689A2 (fr) *	2006-03-21	2007-09-27	Stichting Skeletal Tissue Engineering	Nouveau procede d'induction de la differenciation de cellules souches et progenitrices
MX2009001445A (es) *	2006-08-07	2009-02-18	Genzyme Corp	Terapia de combinacion.
US7883698B2 (en) *	2007-01-17	2011-02-08	Maria Michejda	Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20110245265A1 (en) *	2008-08-29	2011-10-06	Genzyme Corporation	Cxcr4 antagonists for kidney injury
US20130039882A1 (en) *	2009-10-28	2013-02-14	Henry Ford Health System	Method to mitigate injury from radiation exposure
CN101716167B (zh) *	2009-12-08	2011-12-28	中国人民解放军军事医学科学院野战输血研究所	一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
CA2807552A1 (fr)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Acides nucleiques modifies et leurs procedes d'utilisation
US20150030561A1 (en)	2011-05-16	2015-01-29	Genzyme Corp.	Use of CXCR4 Antagonists
EP2968563A4 (fr) *	2013-03-15	2016-11-30	Leonard B Miller	Traitement combiné pour améliorer la cicatrisation de tissu mou, la cicatrisation de greffe de tissu adipeux, la cicatrisation osseuse endochondrale et l'ostéointégration
US9988973B2 (en)	2015-01-06	2018-06-05	Hamilton Sundstrand Corporation	Water injector for aviation cooling system
HK1259026A1 (zh)	2015-09-18	2019-11-22	综合医院公司以麻省总医院名义经营	用於治疗癌症的抗趋除剂的局部递送
ES2907489T3 (es)	2015-12-14	2022-04-25	X4 Pharmaceuticals Inc	Métodos para el tratamiento del cáncer
WO2017106332A1 (fr)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Méthodes de traitement du cancer
WO2017106630A1 (fr)	2015-12-18	2017-06-22	The General Hospital Corporation	Polymères polyacétal, conjugués, particules et utilisations associées
HUE060517T2 (hu)	2015-12-22	2023-03-28	X4 Pharmaceuticals Inc	Immunhiányos betegség kezelésére szolgáló eljárások
WO2017177230A1 (fr)	2016-04-08	2017-10-12	X4 Pharmaceuticals, Inc.	Méthodes de traitement du cancer
WO2017216373A1 (fr) *	2016-06-16	2017-12-21	Centre National De La Recherche Scientifique	Composés de liaison au récepteur cxcr4 utiles pour augmenter le taux d'interféron
CA3027500A1 (fr)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Inhibiteurs de cxcr4 et leurs utilisations
WO2017223229A1 (fr)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Inhibiteurs de cxcr4 et leurs utilisations
JP7054529B2 (ja)	2016-06-21	2022-04-14	エックス４ファーマシューティカルズ，インコーポレイテッド	Ｃｘｃｒ４阻害剤およびその使用
US11453706B2 (en)	2016-09-09	2022-09-27	The General Hospital Corporation	HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
EP3509609A4 (fr)	2016-09-09	2021-01-20	The General Hospital Corporation	Protéine hsp hybride avec un agent anti-chimiorépulsif pour le traitement du cancer
WO2018049120A1 (fr)	2016-09-09	2018-03-15	The General Hospital Corporation	Cellules présentatrices d'antigène ex vivo ou cellules t cd positives activées pour le traitement du cancer
WO2018106738A1 (fr)	2016-12-05	2018-06-14	Massachusetts Institute Of Technology	Polymères en étoile à bras en brosse, conjugués et particules, et leurs utilisations
CN111712262A (zh) *	2017-12-06	2020-09-25	美真达治疗公司	用于动员造血干细胞和祖细胞的给药方案
US10058573B1 (en)	2017-12-06	2018-08-28	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en)	2017-12-06	2022-03-01	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10709763B2 (en) *	2017-12-19	2020-07-14	Gpcr Therapeutics, Inc.	GPCR heteromer inhibitors and uses thereof
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en)	2019-10-08	2024-08-13	The Regents Of The University Of California	Methods and compositions for hematopoietic stem cell mobilization
JP2023517956A (ja)	2020-03-10	2023-04-27	エックス４ファーマシューティカルズ，インコーポレイテッド	好中球減少症を処置する方法
EP4146797A1 (fr)	2020-05-06	2023-03-15	Orchard Therapeutics (Europe) Limited	Traitement pour les maladies neurodégénératives
JP2024536246A (ja)	2021-10-01	2024-10-04	ヤンセンファーマシューティカエヌ．ベー．	前駆細胞産生を増加させる方法
WO2025224720A1 (fr)	2024-04-24	2025-10-30	Biolinerx Ltd.	Procédés de sélection de schéma thérapeutique contre des tumeurs solides
CN118987175A (zh) *	2024-08-13	2024-11-22	广东壹加再生医学研究院有限公司	普乐沙褔联合粒细胞集落刺激因子在制备治疗脑梗死的药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US562476A (en) *		1896-06-23		Combined fence-wire reel and straightener
US4111199A (en) *	1977-03-31	1978-09-05	Isaac Djerassi	Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de)	1987-08-24	1989-03-16	Schering Ag	Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr)	1989-03-20	1990-09-21	Centre Nat Rech Scient	Procede de preparation de tetramines cycliques monofonctionnalisees
ES2116291T3 (es)	1989-10-23	1998-07-16	Nycomed Salutar Inc	Agentes quelantes de metales en sitios multiples.
US6001826A (en)	1989-12-21	1999-12-14	Anormed, Inc.	Chemical compounds
US5021409A (en)	1989-12-21	1991-06-04	Johnson Matthey Plc	Antiviral cyclic polyamines
FR2672051B1 (fr)	1991-01-24	1993-05-21	Guerbet Sa	Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en)	1991-03-15	1991-05-01	Johnson Matthey Plc	Improvements in chemical compounds
GB9126677D0 (en)	1991-12-16	1992-02-12	Johnson Matthey Plc	Improvements in chemical compounds
EP0670735B1 (fr)	1992-11-13	1997-04-02	Board Of Regents Of The University Of Washington	Peripherisation de cellules souches hematopoietiques
GB9400411D0 (en)	1994-01-11	1994-03-09	Johnson Matthey Plc	Improvements in chemical compounds
JPH08127539A (ja) *	1994-10-31	1996-05-21	Ajinomoto Co Inc	ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
GB9502022D0 (en) *	1995-02-02	1995-03-22	Abuljadayel Ilham M S	A method for preparing lymphohaematopoietic progenitor cells
US5612478A (en)	1995-03-30	1997-03-18	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en)	1995-05-02	1997-02-25	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) *	1995-06-05	1997-02-25	Nippon Kayaku Co Ltd	末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en)	1996-06-06	2003-01-14	Anormed, Inc.	Antiviral compounds
GB9511357D0 (en)	1995-06-06	1995-08-02	Johnson Matthey Plc	Improved antiviral compounds
US5811544A (en) *	1995-08-28	1998-09-22	Johnson Matthey Plc	Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (fr) *	2000-05-09	2001-11-09	The University Of British Columbia	Traitement antagoniste cxcr4 de cellules hematopoietiques
EP2308996A1 (fr) *	1998-03-30	2011-04-13	NorthWest Biotherapeutics, Inc.	Applications therapeutiques et diagnostiques basées sur le role des gêne cxcr-4 et SDF-1 dans l'oncogénèse
AU4696899A (en) *	1998-06-19	2000-01-05	General Hospital Corporation, The	Modulating platelet function
CA2244554A1 (fr) *	1998-07-30	2000-01-30	Vasogen Inc.	Inhibition d'une greffe par rapport a la maladie d'un hote
CA2344653A1 (fr) *	1998-09-29	2000-04-06	Gamida Cell Ltd.	Procedes de regulation de la proliferation et de la differentiation de cellules souches et precurseurs
WO2000028987A1 (fr) *	1998-11-17	2000-05-25	Smithkline Beecham Corporation	Traitements de la thromcocytopenie
EP1016413A1 (fr)	1998-12-30	2000-07-05	Applied Research Systems ARS Holding N.V.	Hormone de croissance humaine (HGH) pour stimuler la mobilisation de cellules souches hematopoietiques pluripotentes
US6365583B1 (en) *	1999-02-02	2002-04-02	Anormed, Inc.	Methods to enhance white blood cell count
AP1654A (en)	1999-03-24	2006-09-01	Anormed Inc	Chemokine receptor binding heterocyclic compounds.
WO2000066112A1 (fr) *	1999-05-03	2000-11-09	Smithkline Beecham Corporation	Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine
WO2001044229A1 (fr) *	1999-12-17	2001-06-21	Anormed Inc.	Recepteur de chemokine liant des composes heterocycliques
DE60103052T2 (de)	2000-05-09	2005-03-03	The University Of British Columbia, Vancouver	Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CA2412436C (fr) *	2000-06-05	2013-05-21	The Trustees Of Columbia University In The City Of New York	Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
DK1317451T3 (da)	2000-09-15	2006-12-18	Anormed Inc	Kemokinreceptorbindende heterocykliske forbindelser
MXPA03002325A (es)	2000-09-15	2003-06-24	Anormed Inc	Compuestos heterociclicos que se unen a receptor de quimiocina.
US6864265B2 (en)	2000-09-15	2005-03-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
MXPA03002772A (es)	2000-09-29	2003-07-28	Anormed Inc	Procedimiento para la preparacion de poliaminas ciclicas que contienen nitrogeno en el anillo n-1 protegidos y productos de los mismos.
MXPA03006542A (es)	2001-01-23	2003-09-22	P & G Clairol Inc	Intermediarios primarios para la coloracion oxidativa del cabello.
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
JP5137288B2 (ja)	2001-07-31	2013-02-06	アノーメッドインコーポレイティド	前駆／幹細胞を動員する方法
CN1596255A (zh)	2001-12-21	2005-03-16	阿诺麦德股份有限公司	具有强效的与趋化因子受体结合的杂环化合物
DE102014206089B4 (de)	2014-03-31	2018-01-18	BSH Hausgeräte GmbH	Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

2002
- 2002-07-30 JP JP2003516507A patent/JP5137288B2/ja not_active Expired - Lifetime
- 2002-07-30 ES ES10184509T patent/ES2742730T3/es not_active Expired - Lifetime
- 2002-07-30 PT PT10184509T patent/PT2371361T/pt unknown
- 2002-07-30 PT PT02750370T patent/PT1411918E/pt unknown
- 2002-07-30 KR KR1020097024731A patent/KR100996378B1/ko not_active Expired - Lifetime
- 2002-07-30 CA CA2455559A patent/CA2455559C/fr not_active Expired - Lifetime
- 2002-07-30 PL PL02364673A patent/PL364673A1/xx unknown
- 2002-07-30 HU HU0402360A patent/HUP0402360A2/hu unknown
- 2002-07-30 CN CN201010282230.3A patent/CN102302493B/zh not_active Expired - Lifetime
- 2002-07-30 DK DK10184509.7T patent/DK2371361T3/da active
- 2002-07-30 SI SI200231096T patent/SI2371361T1/sl unknown
- 2002-07-30 LT LTEP10184509.7T patent/LT2371361T/lt unknown
- 2002-07-30 BR BRPI0211570 patent/BRPI0211570B8/pt not_active IP Right Cessation
- 2002-07-30 SI SI200230976T patent/SI1411918T1/sl unknown
- 2002-07-30 AU AU2002318927A patent/AU2002318927B2/en not_active Expired
- 2002-07-30 EP EP10184509.7A patent/EP2371361B1/fr not_active Revoked
- 2002-07-30 WO PCT/US2002/024212 patent/WO2003011277A2/fr not_active Ceased
- 2002-07-30 IL IL15931202A patent/IL159312A0/xx unknown
- 2002-07-30 DK DK02750370.5T patent/DK1411918T3/da active
- 2002-07-30 CN CN028149955A patent/CN1561208B/zh not_active Expired - Lifetime
- 2002-07-30 MX MXPA04000982A patent/MXPA04000982A/es active IP Right Grant
- 2002-07-30 NZ NZ530169A patent/NZ530169A/en not_active IP Right Cessation
- 2002-07-30 US US10/209,001 patent/US6987102B2/en not_active Expired - Lifetime
- 2002-07-30 RU RU2004105961/15A patent/RU2309741C2/ru active Protection Beyond IP Right Term
- 2002-07-30 EP EP02750370A patent/EP1411918B1/fr not_active Revoked
- 2002-07-30 KR KR10-2004-7001333A patent/KR20040020075A/ko not_active Ceased
- 2002-07-30 AT AT02750370T patent/ATE538785T1/de active
- 2002-07-30 ES ES02750370T patent/ES2380009T3/es not_active Expired - Lifetime
- 2002-07-30 EP EP19179517.8A patent/EP3632425A1/fr not_active Withdrawn
2003
- 2003-12-11 IL IL159312A patent/IL159312A/en active IP Right Grant
2004
- 2004-01-27 ZA ZA2004/00658A patent/ZA200400658B/en unknown
- 2004-01-29 NO NO20040407A patent/NO336989B1/no active Protection Beyond IP Right Term
2005
- 2005-11-08 US US11/269,773 patent/US7935692B2/en not_active Expired - Lifetime
2006
- 2006-06-02 US US11/446,390 patent/US20060223180A1/en not_active Abandoned
2007
- 2007-08-20 US US11/841,837 patent/US7897590B2/en not_active Expired - Lifetime
2008
- 2008-04-11 JP JP2008104148A patent/JP2008195730A/ja not_active Withdrawn
2011
- 2011-02-08 US US13/023,381 patent/US20110129448A1/en not_active Abandoned
2012
- 2012-03-07 CY CY20121100223T patent/CY1112633T1/el unknown
- 2012-06-27 CY CY2012017C patent/CY2012017I2/el unknown
- 2012-06-27 LU LU92033C patent/LU92033I2/fr unknown
- 2012-06-28 FR FR12C0042C patent/FR12C0042I1/fr active Active
- 2012-06-28 NL NL300537C patent/NL300537I2/nl unknown
2013
- 2013-03-14 US US13/826,913 patent/US20130273009A1/en not_active Abandoned
2014
- 2014-10-03 US US14/506,297 patent/US20150246019A1/en not_active Abandoned
2015
- 2015-05-27 NO NO20150674A patent/NO344632B1/no not_active IP Right Cessation
2016
- 2016-03-18 US US15/074,836 patent/US20170049747A1/en not_active Abandoned
- 2016-06-10 NO NO2016011C patent/NO2016011I1/no unknown
2018
- 2018-08-21 US US16/107,761 patent/US20190216773A1/en not_active Abandoned
2019
- 2019-08-20 CY CY20191100889T patent/CY1122199T1/el unknown
- 2019-10-10 FR FR19C1058C patent/FR19C1058I2/fr active Active
- 2019-10-14 CY CY2019038C patent/CY2019038I2/el unknown
- 2019-10-23 BE BE2019C544C patent/BE2019C544I2/fr unknown
- 2019-11-19 LT LTPA2019018C patent/LTC2371361I2/lt unknown
- 2019-11-26 LU LU00139C patent/LUC00139I2/fr unknown
2020
- 2020-01-22 NL NL301031C patent/NL301031I2/nl unknown
- 2020-03-05 NO NO2020003C patent/NO2020003I1/no unknown

Also Published As

Publication number	Publication date
NL301031I1 (nl)	2020-02-05
JP2004538303A (ja)	2004-12-24
US20150246019A1 (en)	2015-09-03
CY1112633T1 (el)	2015-08-05
NO344632B1 (no)	2020-02-17
PT1411918E (pt)	2012-03-06
HK1063005A1 (en)	2004-12-10
US20110129448A1 (en)	2011-06-02
DK2371361T3 (da)	2019-08-19
EP3632425A1 (fr)	2020-04-08
PT2371361T (pt)	2019-09-10
EP1411918A2 (fr)	2004-04-28
KR20040020075A (ko)	2004-03-06
LTC2371361I2 (lt)	2021-09-27
LUC00139I1 (fr)	2019-11-27
ES2380009T3 (es)	2012-05-07
US20190216773A1 (en)	2019-07-18
NO336989B1 (no)	2015-12-14
CY2012017I1 (el)	2015-08-05
ZA200400658B (en)	2005-07-27
US7897590B2 (en)	2011-03-01
BR0211570A (pt)	2004-07-13
RU2004105961A (ru)	2005-03-20
LU92033I9 (fr)	2019-01-03
SI1411918T1 (sl)	2012-04-30
MXPA04000982A (es)	2004-04-20
JP5137288B2 (ja)	2013-02-06
CN102302493A (zh)	2012-01-04
CY2019038I1 (el)	2020-05-29
US6987102B2 (en)	2006-01-17
BRPI0211570B8 (pt)	2021-05-25
KR100996378B1 (ko)	2010-11-25
NL300537I2 (fr)	2017-02-02
CN1561208A (zh)	2005-01-05
NZ530169A (en)	2007-04-27
WO2003011277A2 (fr)	2003-02-13
FR19C1058I2 (fr)	2020-10-23
IL159312A0 (en)	2004-06-01
CA2455559A1 (fr)	2003-02-13
AU2002318927B2 (en)	2007-01-04
KR20090130152A (ko)	2009-12-17
LT2371361T (lt)	2019-09-10
US20170049747A1 (en)	2017-02-23
HUP0402360A2 (hu)	2005-02-28
CY2012017I2 (el)	2015-08-05
IL159312A (en)	2015-05-31
LUC00139I2 (fr)	2021-02-10
ATE538785T1 (de)	2012-01-15
EP2371361A1 (fr)	2011-10-05
US20130273009A1 (en)	2013-10-17
FR19C1058I1 (fr)	2019-11-22
JP2008195730A (ja)	2008-08-28
NO2016011I1 (no)	2016-06-10
CY1122199T1 (el)	2020-05-29
US20060193826A1 (en)	2006-08-31
US20080063624A1 (en)	2008-03-13
RU2309741C2 (ru)	2007-11-10
NL301031I2 (nl)	2020-07-20
CA2455559C (fr)	2012-01-10
SI2371361T1 (sl)	2019-10-30
US20030130250A1 (en)	2003-07-10
US20060223180A1 (en)	2006-10-05
NO2020003I1 (no)	2020-03-05
EP1411918A4 (fr)	2007-11-14
BE2019C544I2 (fr)	2021-07-19
NO20150674A1 (no)	2015-05-27
CN102302493B (zh)	2015-08-12
CN1561208B (zh)	2010-11-10
EP2371361B1 (fr)	2019-08-07
FR12C0042I1 (fr)	2012-08-10
WO2003011277A3 (fr)	2003-05-22
DK1411918T3 (da)	2012-04-23
LTPA2019018I1 (lt)	2019-12-10
US7935692B2 (en)	2011-05-03
PL364673A1 (en)	2004-12-13
BRPI0211570B1 (pt)	2020-01-28
CY2019038I2 (el)	2020-05-29
NO20040407L (no)	2004-03-19
EP1411918B1 (fr)	2011-12-28
ES2742730T3 (es)	2020-02-17

Publication	Publication Date	Title
LTC2371361I2 (lt)	2021-09-27	Pirmtakų/kamieninių ląstelių suaktyvinimo būdai
AP1497A (en)	2005-11-20	Methods and compositions to enhance white blood cell count.
MXPA05003193A (es)	2005-06-08	Compuesto de adenina novedoso y uso del mismo.
HUP0004259A2 (hu)	2001-04-28	VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
EA200200708A1 (ru)	2003-02-27	Производные бензазола и их применение в качестве модуляторов jnk
EA200501148A1 (ru)	2006-04-28	Пиридилоксиметильные и бензизоксазольные азабициклические производные
ES2262504T3 (es)	2006-12-01	Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4.
WO1999023092A3 (fr)	1999-08-05	3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine
MA27576A1 (fr)	2005-10-03	Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR026222A1 (es)	2003-01-29	Compuestos derivados de acido antranilico
DK1209166T3 (da)	2004-07-26	Hidtil ukendte A-500 359-derivater
NO20012943L (no)	2001-08-14	Nye heterocykliske forbindelser og farmasöytiske sammensetninger inneholdende det samme
OA09239A (fr)	1992-06-30	"Nouveaux céphèmes et procédés pour leur préparation".
EA200101050A1 (ru)	2002-04-25	Замещенные бензолактамные соединения
EA200000527A2 (ru)	2000-12-25	Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
DE69904025D1 (de)	2003-01-02	Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen
WO2007106063A3 (fr)	2007-12-21	Procédés servant à accroître le débit sanguin et/ou à favoriser la régénération d'un tissu
EA200001157A2 (ru)	2001-06-25	Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
FR2823749B1 (fr)	2004-02-20	Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant